MegaPro’ s MPB-1734 Expected to Seek Prostate Cancer NDA via 505(b)(2) Pathway Supported by Bioequivalence Study
View all comments(0)
|
Taipei, June 30, 2025 —MegaPro Biomedical Co., Ltd. (hereafter referred to as “MegaPro”, TPEx: 6827) announced that it has received a written response from the U.S. FDA regarding its novel anti-cancer formulation, MPB-1734, following a Type C meeting. The formulation is based onMegePro’s proprietary nano-micelle platform and does not contian Tween-80. Based on current nonclinical (animal) and partial human clinical data, FDA considered MPB-1734 for the treatment of prostate cancer may be eligible to use a bioequivalence (BE) study served as a scientific bridge, allowing MPB-1734 to seek regulatory approval through the 505(b)(2) NDA pathway. Dr. Yuan-Hung Hsu, President of MegaPro, explained that the company’s nano-micelle technology is designed to improve the solubility of poorly water-soluble hydrophobic drugs. Traditionally, these drugs use Tween-80 as a solubilizer. However, scientific studies has indicated that Tween-80 is associated with hypersensitivity reactions. For instance, the label of the marketed drug Jevtana® includes a black box warning highlighting the risk of severe allergic reactions due to its Tween-80 content,. MPB-1734, is a Tween-80 free formulation, offering improved drug stability and solubility while reducing excipient-associated risks. Based on the preclinical and early clinical pharmacokinetic data showing similarity to the reference drug, the US FDA has indicated that MPB-1734 may be eligible for the 505(b)(2) NDA pathway through a bioequivalence study. MPB-1734 is a novel formulation taegeting the current market of Jevtana®. According to Verified Market Reports, the global market size of Jevtana is USD $350 million in 2024 and projected to reach $750 million by 2033, with a compound annual growth rate (CAGR) of 9.2%,. Key drivers include increasing awareness of prostate cancer, an aging global population, earlier diagnosis, longer survival, and the need for advanced treatment. As a Tween-80 free formulation, MPB-1734 is well positioned as c competitive alternative in a growing market segment. Dr. Jassy Wang, CEO of MegaPro, added that recent market cases—such as Cinvanti (a Tween-80 free antiemetic) and BEIZRAY (Tween-80 free paclitaxel) demonstrated that new formulation without Tween-80 not only obtained regulatory approvals via bioequivalence studies but also rapidly gained market share or achieved successful out-licensing after launch. This validates MegaPro's commercial potential of its nano-micelle platform. The company aims to apply this technology to re-formulate hydrophobic drugs, thus to accelerate regulatory timeline and reach new milestone in business growth.
30/06/2025 Dissemination of a Financial Press Release, transmitted by EQS News. |
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Nvidia Q3 Revenue Surges 103%, Next-Quarter Revenue Guidance Reaches $130 Billion, Shares Briefly Rise Over 4% After Hours

【US Pre-Market】Nvidia Rises Nearly 1% Ahead of Post-Market Earnings as US Tightens AI Chip Remote Access Restrictions

Micron Plunges 8% in a Day Near Six-Month Low: Can $700 Support Hold?

US October Retail Sales Preview: Will US Consumer Spending Cool? Fed December Rate Hike Expectations Face Another Test

Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150?








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.